ScholarLens Back to search
2004•Huaxi yaoxue zazhiRequires access

Clinical observation on the effects of low dosage imatinib to chronic myelogenous leukemia in blast crisis

Zhonggan Huang

Open publisher page 0 citations

Abstract

OBJECTIVE To observe the efficacy and safety of low dosage imatinib in the treatment of chronic myelogenous leukemia in the blast crisis (CML-BC). METHODS 8 patients with CML-BC who had received interferon and hydroxyurea were treated with 200-300 mg·d -1 of oral imatinib for 18 to 94 weeks. RESULS 4 patients achieved complete hematological response and 2 patients achieved major hematological response.Imatinib induced major cytogenetic response in 2 patients and improved cytogenetic response in 2 patients. The adverse effects were little and tolerable. CONCLUSION Low dosage imatinib has also improved hematologic and cytogenetic responses in patients with CML-BC who had failed in previous therapy of interferon and hydroxyurea. Further investigation is required for long_term effects of low dosage imatinib on CML-BC.

About this research paper

What this paper is about

OBJECTIVE To observe the efficacy and safety of low dosage imatinib in the treatment of chronic myelogenous leukemia in the blast crisis (CML-BC). METHODS 8 patients with CML-BC who had received interferon and hydroxyurea were treated with 200-300 mg·d -1 of oral imatinib for 18 to 94 weeks. RESULS 4 patients achieved complete hematological response and 2 patients achieved major hematological response.Imatinib induced major cytogenetic response in 2 patients and improved cytogenetic response in 2 patients. The adverse effects were little and tolerable. CONCLUSION Low dosage imatinib has also improved hematologic and cytogenetic responses in patients with CML-BC who had failed in previous therapy of interferon and hydroxyurea. Further investigation is required for long_term effects of low dosage imatinib on CML-BC.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

OBJECTIVE To observe the efficacy and safety of low dosage imatinib in the treatment of chronic myelogenous leukemia in the blast crisis (CML-BC). METHODS 8 patients with CML-BC who had received interferon and hydroxyurea were treated with 200-300 mg·d -1 of oral imatinib for 18 to 94 weeks. RESULS 4 patients achieved complete hematological response and 2 patients achieved major hematological response.Imatinib induced major cytogenetic response in 2 patients and improved cytogenetic response in 2 patients. The adverse effects were little and tolerable. CONCLUSION Low dosage imatinib has also improved hematologic and cytogenetic responses in patients with CML-BC who had failed in previous therapy of interferon and hydroxyurea. Further investigation is required for long_term effects of low dosage imatinib on CML-BC.

Key concepts: Imatinib, Chronic myelogenous leukemia, Blast Crisis, Adverse effect, Leukemia, Internal medicine, Imatinib mesylate, Pharmacology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Clinical observation on the effects of low dosage imatinib to chronic myelogenous leukemia in blast crisis — Research Paper | ScholarLens